ConductScience.org, home
Diseases
API referenceFor AI assistants

Disease · MONDO_0001572

leiomyoma

6 sourcesdiseases-2026-09-18-0.1.0

Download JSON
Cite this record

ConductScience Library. leiomyoma. Diseases, record MONDO_0001572. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0001572

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name
leiomyoma
Open Targets
Open Targets ID
MONDO_0001572
Open Targets
Other names
fibroid, fibroid neoplasm, fibroid tumor, fibroid tumour, leiomyoma, benign, leiomyomatous neoplasm (morphologic abnormality), leiomyomatous tumour
Open Targets
Disease Ontology
DOID:127
Disease Ontology
MeSH
D007889
MeSH
NCI Thesaurus
C3157
NCI Thesaurus
Highest stage of its drugs
Approval, for 6 of its 13 drugs, from EMA Human Drugs
Open Targets

Drugs13

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

DrugChEMBL IDTypeOpen Targets' stageStage reported byReportsOf them trialsTrials shown hereSource
ULIPRISTAL ACETATECHEMBL260538Small moleculeApprovalEMA Human Drugs, at withdrawal211Drugs and targets
ESTRADIOLCHEMBL135Small moleculeApprovalEMA Human Drugs100Drugs and targets
LINZAGOLIX CHOLINECHEMBL4298171Small moleculeApprovalEMA Human Drugs100Drugs and targets
NORETHINDRONE ACETATECHEMBL1201146Small moleculeApprovalEMA Human Drugs100Drugs and targets
RELUGOLIXCHEMBL1800159Small moleculeApprovalEMA Human Drugs100Drugs and targets
ULIPRISTALCHEMBL2103846Small moleculeApprovalEMA Human Drugs, at withdrawal100Drugs and targets
VILAPRISANCHEMBL3989936Small moleculePhase 3ClinicalTrials.gov111Drugs and targets
CHORIOGONADOTROPIN ALFACHEMBL1201464ProteinPhase 1/2ClinicalTrials.gov110Drugs and targets
GONADORELINCHEMBL1007ProteinPhase 1/2ClinicalTrials.gov110Drugs and targets
GONADORELIN ACETATECHEMBL1200511ProteinPhase 1/2ClinicalTrials.gov110Drugs and targets

1 to 10 of 13

See all 13 drugs

Targets6

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

TargetProteinIts drugs that act on itMechanismsHighest stage of those drugsGene in GenesSource
GNRHRGonadotropin-releasing hormone receptor4Gonadotropin-releasing hormone receptor agonist; Gonadotropin-releasing hormone receptor antagonistApprovalhttps://conductscience.org/library/genes/2798Drugs and targets
PGRProgesterone receptor4Progesterone receptor agonist; Progesterone receptor modulatorApprovalhttps://conductscience.org/library/genes/5241Drugs and targets
LHCGRLutropin-choriogonadotropic hormone receptor3Luteinizing hormone/Choriogonadotropin receptor agonistPhase 1/2https://conductscience.org/library/genes/3973Drugs and targets
ESR1Estrogen receptor1Estrogen receptor alpha agonistApprovalhttps://conductscience.org/library/genes/2099Drugs and targets
FSHRFollicle-stimulating hormone receptor1Follicle stimulating hormone receptor agonistPhase 1/2https://conductscience.org/library/genes/2492Drugs and targets
PLGPlasminogen1Plasminogen inhibitorUnknownhttps://conductscience.org/library/genes/5340Drugs and targets

Trials3

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

TrialTitlePhaseParticipantsResults first postedConditionsDrugsLinked bySource
NCT03194646Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine FibroidsPhase 31,2722021-08-26Uterine FibroidsVILAPRISANOpen Targets' reading of its recordClinicalTrials.gov
NCT02147158A Study of the Efficacy and Safety of Ulipristal Acetate Intermittent Treatment for Abnormal Uterine Bleeding Associated With LeiomyomasPhase 34322019-06-04Leiomyoma, Uterine HemorrhageULIPRISTAL ACETATEIts record names the diseaseClinicalTrials.gov
NCT03505502Reducing Blood Loss During Cesarean Myomectomy With Tranexamic AcidNot applicable120Cesarean Section ComplicationsTRANEXAMIC ACIDOpen Targets' reading of its recordClinicalTrials.gov

Comparisons in its trials0

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

None in this release.

Papers from its trials3

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMIDListed asTrials listing itSource
31444600DERIVED1PubMed
30969201DERIVED1PubMed
30303900DERIVED1PubMed

Data dates

The date of each source this release read.

Open Targets
2026-09-18
Open Targets
Drug links and their checks, from Drugs and targets
2026-09-18
Drugs and targets
ClinicalTrials.gov, from Trials
2026-11-12
Trials
Comparisons, from Trial comparisons
2026-03-23
Trial comparisons
PubMed, for the checks
2026-11-06
PubMed
MeSH, for the checks
2026-11-10
MeSH

Sources 6

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • NLM's MeSHNLM's terms
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • NLM's MeSHNLM's
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0001572

GET https://conductscience.org/api/diseases/v1/MONDO_0001572/drugs

API referenceFor AI assistants